BerGenBio ASA (BGBIO.OL)

11.90 +0.05 (+0.42%) 收市：04:25PM CEST

BerGenBio ASA

Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 15

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Martin Olin	Chief Executive Officer	8.55M	無	1969
Mr. Rune Skeie	Chief Financial Officer	2.57M	無	1973
Ms. Cristina Oliva M.D.	Chief Medical Officer	4.88M	無	無
Graham Morell	Head of IR	無	無	無
Ms. Gayle M. Mills M.B.A	Chief Business Officer	無	無	1955
Dr. Akil Jackson	Medical Director	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 NOK。

描述

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.

公司管治

截至 無 止，BerGenBio ASA 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。